Panacos is engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent
serious infectious disease. The Company has an expanding pipeline of promising anti-infective drug candidates for
major markets with significant, unmet medical needs.
|
Panacos Announces Voluntary Decision to Delist Common Stock from Nasdaq and Terminate SEC Registration of Common Stock
Panacos Provides Corporate and Strategic Update
|
Frequently Asked Questions Regarding Voluntary Delisting from Nasdaq 
View ICAAC Presentation
Sunday, October 26, 8:30 am EST View ICAAC Poster
Sunday, October 26, 11:15 am - 12:15 pm EST
To sign up for automatic event updates, please visit our E-mail Alerts page.
|
